Staff Login
Japanese
| English
Contact Us
List
Search
Browse
Registration
Statistics
Search
Home
List
Reference
Patent
Reference - List
When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
«
»
7 Hits
Search Condition : Filter (MeSH = Protein Kinase Inhibitors / pharmacokinetics)
Species
Resource
RRC ID
Title
Journal
Published
Link
Human and Animal Cells
HGC-27(RCB0500)
67497
Discovery of novel ceramide analogs with favorable pharmacokinetic properties and combination with AKT inhibitor against colon cancer.
Eur J Med Chem
2021-4-5
Pubmed
Full text
Human and Animal Cells
KP4(RCB1005)
65155
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Clin Cancer Res
2020-3-15
Pubmed
Full text
Human and Animal Cells
Ba/F3
65071
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Mol Cancer Ther
2017-6-1
Pubmed
Full text
Human and Animal Cells
PC-9(RCB4455)
65037
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
2017-4-13
Pubmed
Full text
Human and Animal Cells
KP4(RCB1005)
64294
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
CPT Pharmacometrics Syst Pharmacol
2021-5-1
Pubmed
Full text
Human and Animal Cells
WI-38(RCB0702)
,
A549(RCB0098)
63540
Assessment of transporter-mediated efflux of nintedanib using
in vitro
cell line models of idiopathic pulmonary fibrosis.
Pharmazie
2020-8-1
Pubmed
Full text
Human and Animal Cells
CACO-2(RCB0988)
61302
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Cancer Chemother Pharmacol
2014-11-1
Pubmed
Full text